Issue Date: July 11, 2011
Amgen, UCB Test Drug On Shuttle
Amgen and UCB are working with NASA’s Ames Research Center to conduct a preclinical test of an antibody aboard space shuttle Atlantis on the final NASA shuttle mission, which at C&EN press time was scheduled to launch on July 8. Using mice, the experiment will assess the effect of a sclerostin antibody on the bone loss associated with spaceflight. A different sclerostin antibody from the two drug companies is currently in Phase II clinical trials for bone-related conditions.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society